Brilliant Minds in Biotech: Arbor Biotechnologies’ Devyn Smith

In this episode, we speak with Devyn Smith, the CEO of Arbor Biotechnologies, which is an early stage life sciences company pushing the boundaries of biodiscovery.  Arbor has raised over $200 million dollars and is backed by Temasek and other notable investors.

Devyn also serves as Chairman of the Alliance for Regenerative Medicine (ARM) and advises multiple biotech companies. Previously, he was Chief Operations Officer and Head of Strategy at Sigilon Therapeutics, a clinical stage biotechnology company, and before that he was Head of Operations and Strategy, Medicinal Sciences at Pfizer. 

Arbor’s platform employs a diverse set of technologies and techniques – including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening – for accelerating the discovery of proteins for improving human health and sustainability.

Listen on iTunesGoogle Podcasts or Spotify.

Growth Investor Weekly

Discover unique insights from growth investors and leading executives.

Sign up for our weekly newsletter.

Top Go Back
© 2022 GrowthCap, LLC. All rights reserved.

Sign up for GrowthCap Insights